Key considerations around the risks and consequences of hypoglycaemia in people with type 2 diabetes

International Journal of Clinical Practice

Volumn 64, Issue 8, 2010, Pages 1121-1129

  Barnett, A H ^a   Cradock, S ^b   Fisher, M ^c   Hall, G ^d   Hughes, E ^e   Middleton, A ^f  

^a UNIVERSITY DEPARTMENT OF MEDICINE   (United Kingdom)

^b NATIONAL HEALTH SERVICE   (United Kingdom)

^c GLASGOW ROYAL INFIRMARY   (United Kingdom)

^d Haslemere Hospital   (United Kingdom)

^e Esplanade Surgery   (United Kingdom)

^f Fowey River Practice   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

DIPEPTIDYL PEPTIDASE IV INHIBITOR; GLITAZONE DERIVATIVE; INSULIN; METFORMIN; SULFONYLUREA;

ALCOHOL CONSUMPTION; CARDIOVASCULAR RISK; CLINICAL FEATURE; COST OF ILLNESS; EATING HABIT; GLYCEMIC CONTROL; HUMAN; HYPOGLYCEMIA; INCIDENCE; LIFESTYLE; NON INSULIN DEPENDENT DIABETES MELLITUS; PRIORITY JOURNAL; QUALITY OF LIFE; REVIEW; SENESCENCE;

AGE FACTORS; ALCOHOL DRINKING; COST OF ILLNESS; DIABETES MELLITUS, TYPE 2; DIABETIC ANGIOPATHIES; FEAR; HUMANS; HYPOGLYCEMIA; HYPOGLYCEMIC AGENTS; PRACTICE GUIDELINES AS TOPIC; QUALITY OF LIFE; RISK FACTORS; SELF CARE;

EID: 77953845365     PISSN: 13685031     EISSN: 17421241     Source Type: Journal    
DOI: 10.1111/j.1742-1241.2009.02332.x     Document Type: Review

References (52)

1. Stratton IM, Adler AI, Neil HAW et al. Association of glycaemia with macrovascular and microvascular complications of type 2 diabetes (UKPDS 35): prospective observational study. BMJ 2000 321 : 405 412.
2. Holman RR, Paul SK, Bethel MA et al. 10-Year follow-up of intensive glucose control in type 2 diabetes. N Engl J Med 2008 359 : 577 589.
3. BMA, NHS Employers. Quality and Outcomes Framework Guidance for GMS Contract 2009/10 Delivering Investment in General Practice.
4. Briscoe VJ, Davis SN. Hypoglycemia in type 1 and type 2 diabetes: physiology, pathophysiology, and management. Clin Diab 2006 24 : 115 121.
5. 1c measurements. Mayo Clin Proc 2007 82 : 229 236.
6. Zammitt NN, Frier BM. Hypoglycemia in type 2 diabetes: pathophysiology, frequency, and effects of different treatment modalities. Diabetes Care 2005 28 : 2948 2961.
7. Maillardet V. Diabetes Patient Survey Report. East of England Ambulance Service NHS Trust, 2008 A, Egberts EH. Risk of hypoglycaemia with oral antidiabetic agents in patients with Type 2 diabetes. Exp Clin Endocrinol Diabetes 2003 111 : 405 414.
8. Vexiau P, Mavros P, Krishnarajah G et al. Hypoglycaemia in patients with type 2 diabetes treated with a combination of metformin and sulphonylurea therapy in France. Diabetes Obes Metab 2008 10 : 16 24.
9. Workgroup on Hypoglycemia, American Diabetes Association. Defining and reporting hypoglycemia in diabetes: a report from the American Diabetes Association Workgroup on Hypoglycemia. Diabetes Care 2005 28 : 1245 1249.
10. Diabetes UK. Hypoglycaemia. 2008. https://www.diabetes.org.uk/upload/ Hypoglycaemia%209825.pdf (accessed January 2010).
11. Frier BM. Morbidity of hypoglycemia in type 1 diabetes. Diab Res Clin Pract 2004 65 (Suppl. S47 52.
12. Henderson JN, Allen KV, Deary IJ, Frier BM. Hypoglycaemia in insulin-treated type 2 diabetes: frequency, symptoms and impaired awareness. Diab Med 2003 20 : 1016 1021.
13. Leiter LA, Yale JF, Chiasson JL et al. Assessment of the impact of fear of hypoglycemic episodes on glycemic and hypoglycemia management. Can J Diab 2005 29 : 186 192.
14. Miller CD, Phillips LS, Ziemer DC et al. Hypoglycemia in patients with type 2 diabetes mellitus. Arch Intern Med 2001 161 : 1653 1659.
15. Bailey C, Feher MD. Therapies for Diabetes Including Oral Agents and Insulins.
16. Amiel SA, Dixon T, Mann R, Jameson K. Hypoglycaemia in type 2 diabetes. Diabet Med 2008 25 : 245 254.
17. Lundkvist J, Berne C, Bolinder B, Jönsson L. The economic and quality of life impact of hypoglycaemia. Eur J Health Econom 2005 50 : 197 202.
18. Jermendy G, Erdesz D, Nagy L et al. Outcomes of adding second hypoglycemic drug after metformin monotherapy failure among type 2 diabetes in Hungary. Health Qual Life Outcomes 2008 6 : 88.
19. ACCORD study. Effects of intensive glucose lowering in type 2 diabetes. N Engl J Med 2008 358 : 2545 2559.
20. Cryer PE. The barrier of hypoglycemia in diabetes. Diabetes 2008 57 : 3169 3176.
21. Currie CJ, Morgan CL, Poole CD et al. Multivariate models of health-related utility and the fear of hypoglycaemia in people with diabetes. Curr Med Res Opin 2006 22 : 1523 1534.
22. Wild D, von Maltzahn R, Brohan E et al. A critical review of the literature on fear of hypoglycemia in diabetes: implications for diabetes management and patient education. Patient Educ Couns 2007 68 : 10 5.
23. Frier BM. Hypoglycaemia and cognitive function in diabetes. IJCP Suppl 2001 123 : 30 7.
24. Cox DJ, Gonder-Frederick L, Polonsky W et al. Blood glucose awareness training (BGAT-2): long-term benefits. Diabetes Care 2001 24 : 637 642.
25. McAulay V, Deary IJ, Frier BM. Symptoms of hypoglycaemia in people with diabetes. Diabet Med 2001 18 : 690 705.
26. Segal SA, Paramore DS, Cryer PE. Hypoglycemia-associated autonomic failure in advanced type 2 diabetes. Diabetes 2002 51 : 724 732.
27. Hitchen L. Doctors are failing to tell diabetic people about UK driving rules. BMJ 2006 332 : 812.
28. Turnbull FM, Abraira C, Anderson RJ et al. Intensive glucose control and macrovascular outcomes in type 2 diabetes. Diabetologia 2009 52 : 2288 2298.
29. ADVANCE Collaborative Group. Intensive blood glucose control and vascular outcomes in patients with type 2 diabetes. N Engl J Med 2008 358 : 2560 2572.
30. Merck Serono. Glucophage summary of product characteristics http://emc.medicines.org.uk/medicine/1043/SPC/Glucophage/ (accessed January 2010).
31. Leese GP, Wang J, Broomhall J et al. Frequency of severe hypoglycemia requiring emergency treatment in type 1 and type 2 diabetes: a population-based study of health service resource use. Diabetes Care 2003; 26: 117680.
32. UKPDS 33. Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). UK Prospective Diabetes Study (UKPDS) Group. Lancet 1998 352 : 837 853.
33. UK Hypoglycaemia Study Group. Risk of hypoglycaemia in types 1 and 2 diabetes: effects of treatment modalities and their duration. Diabetologia 2007 50 : 1140 1147.
34. UKPDS 34. Effect of intensive blood-glucose control with metformin on complications in overweight patients with type 2 diabetes (UKPDS 34). UK Prospective Diabetes Study (UKPDS) Group. Lancet 1998 352 : 854 865.
35. Stumvoll M, Goldstein BJ, van Haeften TW. Type 2 diabetes: principles of pathogenesis and therapy. Lancet 2005 365 : 1333 1346.
36. Hällsten K, Virtanen KA, Lönnqvist F et al. Rosiglitazone but not metformin enhances insulin- and exercise-stimulated skeletal muscle glucose uptake in patients with newly diagnosed type 2 diabetes. Diabetes 2002 51 : 3479 3485.
37. Kahn SE, Haffner SM, Heise MA et al. Glycemic durability of rosiglitazone, metformin, or glyburide monotherapy. N Engl J Med 2006 355 : 2427 2443.
38. Hamann A, Garcia-Puig J, Paul G et al. Comparison of fixed-dose rosiglitazone/metformin combination therapy with sulphonylurea plus metformin in overweight individuals with Type 2 diabetes inadequately controlled on metformin alone. Exp Clin Endocrinol Diabetes 2008 116 : 6 13.
39. Chou HS, Palmer JP, Jones AR et al. Initial treatment with fixed-dose combination rosiglitazone/glimepiride in patients with previously untreated type 2 diabetes. Diabetes Obes Metab 2008 10 : 626 637.
40. Mattoo V, Eckland D, Widel M et al. Metabolic effects of pioglitazone in combination with insulin in patients with type 2 diabetes mellitus whose disease is not adequately controlled with insulin therapy: results of a six-month, randomized, double-blind, prospective, multicenter, parallel-group study. Clin Ther 2005 27 : 554 567.
41. Drucker DJ. Dipeptidyl peptidase-4 inhibition and the treatment of type 2 diabetes: preclinical biology and mechanisms of action. Diabetes Care 2007 30 : 1335 1343.
42. Bosi E, Camisasca RP, Collober C et al. Effects of vildagliptin on glucose control over 24 weeks in patients with type 2 diabetes inadequately controlled with metformin. Diabetes Care 2007 30 : 890 895.
43. Charbonnel B, Karasik A, Liu J et al. Efficacy and safety of the dipeptidyl peptidase-4 inhibitor sitagliptin added to ongoing metformin therapy in patients with type 2 diabetes inadequately controlled with metformin alone. Diabetes Care 2006 29 : 2638 2643.
44. Ferrannini E, Fonseca V, Zinman B et al. Fifty-two-week efficacy and safety of vildagliptin vs. glimepiride in patients with type 2 diabetes mellitus inadequately controlled on metformin monotherapy. Diabetes Obes Metab 2009 11 : 157 166.
45. Nauck MA, Meininger G, Sheng D et al. Efficacy and safety of the dipeptidyl peptidase-4 inhibitor, sitagliptin, compared with the sulfonylurea, glipizide, in patients with type 2 diabetes inadequately controlled on metformin alone: a randomized, double-blind, non-inferiority trial. Diabetes Obes Metab 2007 9 : 194 205.
46. National Institute for Health and Clinical Excellence. Type 2 Diabetes: Treatment of Type 2 Diabetes. NICE clinical guideline, CG87
47. Chelliah A, Burge MR. Hypoglycaemia in elderly patients with diabetes mellitus: causes and strategies for prevention. Drugs Aging 2004 21 : 511 530.
48. Chau D, Edelman SV. Clinical management of diabetes in the elderly. Clin Diab 2001 19 : 172 175.
49. Whitmer RA, Karter AJ, Yaffe K et al. Hypoglycemic episodes and risk of dementia in older patients with type 2 diabetes mellitus. JAMA 2009 301 : 1565 1572.
50. Huang Z, Sjöholm A. Ethanol acutely stimulates islet blood flow, amplifies insulin secretion, and induces hypoglycemia via nitric oxide and vagally mediated mechanisms. Endocrinology 2008 149 : 232 236.
51. Lager I, Blohmé G, Smith U. Effect of cardioselective and non-selective beta-blockade on the hypoglycaemic response in insulin-dependent diabetics. Lancet 1979 1 : 458 462.
52. Rave K, Flesch S, Kühn-Velten WN et al. Enhancement of blood glucose lowering effect of a sulfonylurea when coadministered with an ACE inhibitor: results of a glucose-clamp study. Diabetes Metab Res Rev 2005 21 : 459 464.